Congratulations to Dave Savage – our co-founder and scientific advisor, the head of Savage Lab Lab, and now UC Berkeley Professor of Biochemistry, Biophysics and Structural Biology!

On #WorldSickleCellDay, we recognize the important progress being made globally to address #SickleCell disease. At Scribe, we're working with leading drug developers like Sanofi to bring in vivo #CRISPR-based therapies to patients in need. Learn more: scribetx.com/press-release-…

Tomorrow at Aspen Ideas Health, join our CEO Benjamin L. Oakes, scientific advisor and Innovative Genomics Institute founder Jennifer Doudna, and CRISPR Therapeutics CEO Samarth Kulkarni for a fireside chat on how next-gen #CRISPR can transform the lives of millions of patients. #GeneEditing #EpigeneticEditing

Livestreaming from #AspenIdeasHealth in 15 minutes! Watch the session on next-gen #CRISPR featuring our CEO Benjamin L. Oakes, Nobel Laureate & Innovative Genomics Institute founder Jennifer Doudna, and CRISPR Therapeutics CEO Samarth Kulkarni: ow.ly/uBga50SmRHA Aspen Ideas #GeneEditing #EpigeneticEditing

Wishing a safe and happy #4thofJuly to everyone celebrating! 🎆

On the FutureBites Podcast, our CEO Benjamin L. Oakes joins host Bruce McCabe to share the immense potential that #EpigeneticEditing holds for the future of medicine. Listen below to learn how these tools work and can unlock new #CRISPR genetic medicines: ow.ly/PzL750SNFXG

In BioSpace, Greg Slabodkin highlights our "data-driven engineering approach—CRISPR by Design—that enables Scribe to build systems that allow for different genome editing outcomes than what’s possible with Cas9." ⬇️ ow.ly/zHjI50T1nCz #CRISPR #GeneEditing #EpigeneticEditing

What does the future of #healthcare look like? In his TEDx Talk UC Berkeley, our CEO Benjamin L. Oakes envisions one-and-done therapies powered by #CRISPR that could treat conditions like cardiometabolic disease. Watch his full talk on YouTube: youtube.com/watch?v=RVdeqA…

We will be at this week's Cold Spring Harbor Laboratory Genome Engineering: #CRISPR Frontiers meeting to discuss our #CRISPRbyDesign approach, advances in our platforms, and how Scribe is engineering the future of #EpigeneticEditing. Looking forward to seeing you there! #cshlcrispr24 #GeneEditing

Another summer, another annual beach day enjoyed with our Scribe family and friends! #NationalBeachDay #BayAreaBiotech

#EpigeneticEditing can silence a target gene instead of permanently editing the genome, says our CEO Benjamin L. Oakes. Learn how this expands our #CRISPR toolbox and opens new doors to creating genetic medicines from this recent Aspen Ideas panel: ow.ly/Jiy250TfJA0

In a new Q&A on #biotech leadership, Big Think interviewed our CEO Benjamin L. Oakes about: 💡 Driving radical innovation in #CRISPR and beyond 📚 Translatable skills from academia to industry 📢 His broader leadership philosophy Read his insights: ow.ly/NwGi50TjuVT